Skip to main content
SpringerLink
Log in

Indolent Cutaneous T-Cell Lymphomas

  • Chapter
  • First Online:
Indolent Lymphomas

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 494 Accesses

Abstract

Primary cutaneous lymphomas are a heterogeneous group of non-Hodgkin lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. Within this group, the majority is derived from T-cells. The different types of cutaneous lymphomas are defined by various clinical manifestations, histological patterns, and immunophenotypic markers. In contrast to the nodal non-Hodgkin lymphomas, primary cutaneous T-cell lymphomas (CTCL) usually represent an indolent disease group and therefore require mostly skin-directed therapies. However, at later stages, certain subtypes run a more aggressive course.

This chapter provides an overview of the most common, indolent CTCL subtypes and summarizes stage-adapted diagnostics and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of hematopoietic and lymphoid tissue (revised 4th edition). Lyon: IARC Press; 2017.

    Google Scholar 

  3. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol. 1999;40:418–25.

    Article  CAS  PubMed  Google Scholar 

  4. van Doorn R, van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000;136:504–10.

    PubMed  Google Scholar 

  5. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857–66.

    Article  PubMed  Google Scholar 

  6. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730–9.

    Article  PubMed  Google Scholar 

  7. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713–22.

    Article  CAS  PubMed  Google Scholar 

  8. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53:1053–63.

    Article  PubMed  Google Scholar 

  9. Smoller BR, Bishop K, Glusac E, Kim YH, Hendrickson M. Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Am J Surg Pathol. 1995;19:1423–30.

    Article  CAS  PubMed  Google Scholar 

  10. Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119:1643–9.

    Article  CAS  PubMed  Google Scholar 

  11. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood. 1998;92:1150–9.

    Article  CAS  PubMed  Google Scholar 

  12. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Massone C, Crisman G, Kerl H, Cerroni L. The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality. Br J Dermatol. 2008;159:881–6.

    Article  CAS  PubMed  Google Scholar 

  14. Rodriguez-Pinilla SM, Ortiz-Romero PL, Monsalvez V, et al. TCR-gamma expression in primary cutaneous T-cell lymphomas. Am J Surg Pathol. 2013;37:375–84.

    Article  PubMed  Google Scholar 

  15. Vega F, Luthra R, Medeiros LJ, et al. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood. 2002;100:3369–73.

    Article  CAS  PubMed  Google Scholar 

  16. Thurber SE, Zhang B, Kim YH, Schrijver I, Zehnder J, Kohler S. T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. J Am Acad Dermatol. 2007;57:782–90.

    Article  PubMed  Google Scholar 

  17. Kirsch IR, Watanabe R, O'Malley JT, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7:308ra158.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome—update 2017. Eur J Cancer. 2017;77:57–74.

    Article  PubMed  Google Scholar 

  19. Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sezary syndrome. Blood. 2016;127:3142–53.

    Article  CAS  PubMed  Google Scholar 

  20. Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv30–40.

    Article  CAS  PubMed  Google Scholar 

  21. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321:1784–90.

    Article  CAS  PubMed  Google Scholar 

  22. Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149:25–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74:154–8.

    Article  PubMed  Google Scholar 

  24. Specht L, Dabaja B, Illidge T, Wilson LD, Hoppe RT. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92:32–9.

    Article  PubMed  Google Scholar 

  25. Quaglino P, Maule M, Prince HM, et al. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol. 2018;28(10):2517–25.

    Article  Google Scholar 

  26. Kamstrup MR, Gniadecki R, Iversen L, et al. Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. Int J Radiat Oncol Biol Phys. 2015;92:138–43.

    Article  PubMed  Google Scholar 

  27. Hoppe RT, Harrison C, Tavallaee M, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72:286–92.

    Article  PubMed  Google Scholar 

  28. Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012;30:4091–7.

    Article  CAS  PubMed  Google Scholar 

  29. Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer. 2005;104:2437–41.

    Article  CAS  PubMed  Google Scholar 

  30. Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390:555–66.

    Article  CAS  PubMed  Google Scholar 

  31. Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33:3750–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33:3759–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19:376–88.

    Article  CAS  PubMed  Google Scholar 

  34. Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:1870–7.

    Article  CAS  PubMed  Google Scholar 

  35. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485–91.

    Article  CAS  PubMed  Google Scholar 

  36. Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125:1883–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1192–204.

    Article  CAS  PubMed  Google Scholar 

  38. Virmani P, Zain J, Rosen ST, Myskowski PL, Querfeld C. Hematopoietic stem cell transplant for mycosis fungoides and Sezary syndrome. Dermatol Clin. 2015;33:807–18.

    Article  CAS  PubMed  Google Scholar 

  39. Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev. 2013;CD008908.

    Google Scholar 

  40. Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010;28:2365–72.

    Article  PubMed  Google Scholar 

  41. Schneeweiss M, Porpaczy E, Koch M, et al. Transformed mycosis fungoides: bridging to allogeneic stem cell transplantation with brentuximab vedotin. Leuk Lymphoma. 2016;57:206–8.

    Article  PubMed  Google Scholar 

  42. Mahevas T, Ram-Wolff C, Battistella M, et al. Dramatic response to brentuximab vedotin in refractory nontransformed CD30(-) mycosis fungoides allowing allogeneic stem cell transplant and long-term complete remission. Br J Dermatol. 2018;180(6):1517–20.

    Article  CAS  Google Scholar 

  43. Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41:597–604.

    Article  CAS  PubMed  Google Scholar 

  44. Nashan D, Faulhaber D, Stander S, Luger TA, Stadler R. Mycosis fungoides: a dermatological masquerader. Br J Dermatol. 2007;156:1–10.

    Article  CAS  PubMed  Google Scholar 

  45. Martinez-Escala ME, Gonzalez BR, Guitart J. Mycosis fungoides variants. Surg Pathol Clin. 2014;7:169–89.

    Article  PubMed  Google Scholar 

  46. Vergier B, Beylot-Barry M, Beylot C, et al. Pilotropic cutaneous T-cell lymphoma without mucinosis. A variant of mycosis fungoides? French Study Group of Cutaneous Lymphomas. Arch Dermatol. 1996;132:683–7.

    Article  CAS  PubMed  Google Scholar 

  47. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002;138:191–8.

    PubMed  Google Scholar 

  48. Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol. 2008;144:738–46.

    Article  PubMed  Google Scholar 

  49. Lehman JS, Cook-Norris RH, Weed BR, et al. Folliculotropic mycosis fungoides: single-center study and systematic review. Arch Dermatol. 2010;146:607–13.

    Article  PubMed  Google Scholar 

  50. Wieser I, Wang C, Alberti-Violetti S, et al. Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. Arch Dermatol Res. 2017;309:453–9.

    Article  CAS  PubMed  Google Scholar 

  51. Hodak E, Amitay-Laish I, Feinmesser M, et al. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement. J Am Acad Dermatol. 2014;70:993–1001.

    Article  PubMed  Google Scholar 

  52. Boulos S, Vaid R, Aladily TN, Ivan DS, Talpur R, Duvic M. Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: a case series of 34 patients. J Am Acad Dermatol. 2014;71:1117–26.

    Article  PubMed  Google Scholar 

  53. van Santen S, Roach RE, van Doorn R, et al. Clinical staging and prognostic factors in folliculotropic mycosis fungoides. JAMA Dermatol. 2016;152:992–1000.

    Article  PubMed  Google Scholar 

  54. Hodak E, Amitay-Laish I, Atzmony L, et al. New insights into folliculotropic mycosis fungoides (FMF): a single-center experience. J Am Acad Dermatol. 2016;75:347–55.

    Article  PubMed  Google Scholar 

  55. Kempf W, Kazakov DV, Schermesser M, et al. Unilesional follicular mycosis fungoides: report of two cases with progression to tumor stage and review of the literature. J Cutan Pathol. 2012;39:853–60.

    Article  PubMed  Google Scholar 

  56. Amitay-Laish I, Feinmesser M, Ben-Amitai D, Fenig E, Sorin D, Hodak E. Unilesional folliculotropic mycosis fungoides: a unique variant of cutaneous lymphoma. J Eur Acad Dermatol Venereol. 2016;30(1):25–9.

    Article  CAS  PubMed  Google Scholar 

  57. van Santen S, Jansen PM, Vermeer MH, Willemze R. Folliculotropic mycosis fungoides presenting with a solitary lesion: clinicopathological features and long-term follow-up data in a series of nine cases. J Cutan Pathol. 2018;45(2):122–8.

    Article  PubMed  Google Scholar 

  58. Gerami P, Guitart J. The spectrum of histopathologic and immunohistochemical findings in folliculotropic mycosis fungoides. Am J Surg Pathol. 2007;31:1430–8.

    Article  PubMed  Google Scholar 

  59. de Masson A, Battistella M, Vignon-Pennamen MD, et al. Syringotropic mycosis fungoides: clinical and histologic features, response to treatment, and outcome in 19 patients. J Am Acad Dermatol. 2014;71:926–34.

    Article  PubMed  Google Scholar 

  60. Tomasini C, Kempf W, Novelli M, et al. Spiky follicular mycosis fungoides: a clinicopathologic study of 8 cases. J Cutan Pathol. 2015;42:164–72.

    Article  PubMed  Google Scholar 

  61. van Santen S, van Doorn R, Neelis KJ, et al. Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2017;177:223–8.

    Article  PubMed  CAS  Google Scholar 

  62. Haghighi B, Smoller BR, LeBoit PE, Warnke RA, Sander CA, Kohler S. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol. 2000;13:502–10.

    Article  CAS  PubMed  Google Scholar 

  63. Steffen C. Ketron-Goodman disease, Woringer-Kolopp disease, and pagetoid reticulosis. Am J Dermatopathol. 2005;27:68–85.

    Article  PubMed  Google Scholar 

  64. LeBoit PE. Granulomatous slack skin. Dermatol Clin. 1994;12:375–89.

    Article  CAS  PubMed  Google Scholar 

  65. Kempf W, Ostheeren-Michaelis S, Paulli M, et al. Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization for Research and Treatment of Cancer (EORTC). Arch Dermatol. 2008;144(12):1609–17.

    Article  PubMed  Google Scholar 

  66. van Haselen CW, Toonstra J, van der Putte SJ, van Dongen JJ, van Hees CL, van Vloten WA. Granulomatous slack skin. Report of three patients with an updated review of the literature. Dermatology. 1998;196:382–91.

    PubMed  Google Scholar 

  67. Clarijs M, Poot F, Laka A, Pirard C, Bourlond A. Granulomatous slack skin: treatment with extensive surgery and review of the literature. Dermatology. 2003;206:393–7.

    Article  PubMed  Google Scholar 

  68. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653–61.

    Article  CAS  PubMed  Google Scholar 

  69. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49:1049–58.

    Article  PubMed  Google Scholar 

  70. de Souza A, el-Azhary RA, Camilleri MJ, Wada DA, Appert DL, Gibson LE. In search of prognostic indicators for lymphomatoid papulosis: a retrospective study of 123 patients. J Am Acad Dermatol. 2012;66:928–37.

    Article  PubMed  Google Scholar 

  71. Wieser I, Wohlmuth C, Nunez CA, Duvic M. Lymphomatoid papulosis in children and adolescents: a systematic review. Am J Clin Dermatol. 2016;17:319–27.

    Article  PubMed  Google Scholar 

  72. Wieser I, Oh CW, Talpur R, Duvic M. Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016;74:59–67.

    Article  PubMed  Google Scholar 

  73. Cordel N, Tressieres B, D'Incan M, et al. Frequency and risk factors for associated lymphomas in patients with lymphomatoid papulosis. Oncologist. 2016;21:76–83.

    Article  PubMed  Google Scholar 

  74. Melchers RC. Willemze R, Bekkenk MW, et al. Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis. J Eur Acad Dermatol Venereol 2020;34:260–66.

    Google Scholar 

  75. Karai LJ, Kadin ME, Hsi ED, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013;37:1173–81.

    Article  PubMed  Google Scholar 

  76. Kempf W. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. Semin Diagn Pathol. 2017;34:22–35.

    Article  PubMed  Google Scholar 

  77. Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24:596–605.

    Article  CAS  PubMed  Google Scholar 

  78. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118:4024–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Bruijn MS, Horvath B, van Voorst Vader PC, Willemze R, Vermeer MH. Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2015;173:1319–22.

    Article  CAS  PubMed  Google Scholar 

  80. Massone C, El-Shabrawi-Caelen L, Kerl H, Cerroni L. The morphologic spectrum of primary cutaneous anaplastic large T-cell lymphoma: a histopathologic study on 66 biopsy specimens from 47 patients with report of rare variants. J Cutan Pathol. 2008;35:46–53.

    PubMed  Google Scholar 

  81. Kummer JA, Vermeer MH, Dukers D, Meijer CJ, Willemze R. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol. 1997;109:636–40.

    Article  CAS  PubMed  Google Scholar 

  82. Boulland ML, Wechsler J, Bagot M, Pulford K, Kanavaros P, Gaulard P. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins. Histopathology. 2000;36:136–44.

    Article  CAS  PubMed  Google Scholar 

  83. Massone C, Cerroni L. Phenotypic variability in primary cutaneous anaplastic large T-cell lymphoma: a study on 35 patients. Am J Dermatopathol. 2014;36:153–7.

    Article  PubMed  Google Scholar 

  84. DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood. 1996;87:3437–41.

    Article  CAS  PubMed  Google Scholar 

  85. Kadin ME, Pinkus JL, Pinkus GS, et al. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol. 2008;32:1421–6.

    Article  PubMed  Google Scholar 

  86. Oschlies I, Lisfeld J, Lamant L, et al. ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica. 2013;98:50–6.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Quintanilla-Martinez L, Jansen PM, Kinney MC, Swerdlow SH, Willemze R. Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol. 2013;139:491–514.

    Article  CAS  PubMed  Google Scholar 

  88. Melchers RC, Willemze R, van de Loo M, et al. Clinical, histologic and molecular characteristics of anaplastic lymphoma kinase-positive primary cutaneous anaplastic large cell lymphoma. Am J Surg Pathol. 2020;44:776–81.

    Google Scholar 

  89. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol. 1996;34:470–81.

    Article  CAS  PubMed  Google Scholar 

  90. Melchers RC, Willemze R, Bekkenk MW, et al. Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2018;179(3):724–31.

    Article  CAS  PubMed  Google Scholar 

  91. Melchers RC, Willemze R, Daniels LA, et al. Recommendations for the optimal radiation dose in patients with primary cutaneous anaplastic large cell lymphoma: a report of the Dutch Cutaneous Lymphoma Group. Int J Radiat Oncol Biol Phys. 2017;99(5):1279–85.

    Article  PubMed  Google Scholar 

  92. Million L, Yi EJ, Wu F, et al. Radiation therapy for primary cutaneous anaplastic large cell lymphoma: an International Lymphoma Radiation Oncology Group multi-institutional experience. Int J Radiat Oncol Biol Phys. 2016;95:1454–9.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Benner MF, Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol. 2009;145:1399–404.

    Article  PubMed  Google Scholar 

  94. Woo DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009;145:667–74.

    Article  PubMed  Google Scholar 

  95. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101:3407–12.

    Article  CAS  PubMed  Google Scholar 

  96. Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;111:838–45.

    Article  CAS  PubMed  Google Scholar 

  97. Huppmann AR, Xi L, Raffeld M, Pittaluga S, Jaffe ES. Subcutaneous panniculitis-like T-cell lymphoma in the pediatric age group: a lymphoma of low malignant potential. Pediatr Blood Cancer. 2013;60:1165–70.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Pincus LB, LeBoit PE, McCalmont TH, et al. Subcutaneous panniculitis-like T-cell lymphoma with overlapping clinicopathologic features of lupus erythematosus: coexistence of 2 entities? Am J Dermatopathol. 2009;31:520–6.

    Article  PubMed  Google Scholar 

  99. Massone C, Chott A, Metze D, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol. 2004;28:719–35.

    Article  PubMed  Google Scholar 

  100. Hoque SR, Child FJ, Whittaker SJ, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol. 2003;148:516–25.

    Article  CAS  PubMed  Google Scholar 

  101. Marzano AV, Berti E, Paulli M, Caputo R. Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol. 2000;136:889–96.

    Article  CAS  PubMed  Google Scholar 

  102. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol. 1998;22:881–93.

    Article  CAS  PubMed  Google Scholar 

  103. Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer. 2003;97:610–27.

    Article  PubMed  Google Scholar 

  104. Mehta N, Wayne AS, Kim YH, et al. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma Leuk. 2012;12:20–5.

    Article  CAS  PubMed  Google Scholar 

  105. Petrella T, Maubec E, Cornillet-Lefebvre P, et al. Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma? Am J Surg Pathol. 2007;31:1887–92.

    Article  PubMed  Google Scholar 

  106. Greenblatt D, Ally M, Child F, et al. Indolent CD8(+) lymphoid proliferation of acral sites: a clinicopathologic study of six patients with some atypical features. J Cutan Pathol. 2013;40:248–58.

    Article  PubMed  Google Scholar 

  107. Li JY, Guitart J, Pulitzer MP, et al. Multicenter case series of indolent small/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face. Am J Dermatopathol. 2014;36:402–8.

    Article  PubMed  Google Scholar 

  108. Wobser M, Roth S, Reinartz T, Rosenwald A, Goebeler M, Geissinger E. CD68 expression is a discriminative feature of indolent cutaneous CD8-positive lymphoid proliferation and distinguishes this lymphoma subtype from other CD8-positive cutaneous lymphomas. Br J Dermatol. 2015;172:1573–80.

    Article  CAS  PubMed  Google Scholar 

  109. Alberti-Violetti S, Fanoni D, Provasi M, Corti L, Venegoni L, Berti E. Primary cutaneous acral CD8 positive T-cell lymphoma with extra-cutaneous involvement: a long-standing case with an unexpected progression. J Cutan Pathol. 2017;44:964–8.

    Article  PubMed  Google Scholar 

  110. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–85.

    Article  CAS  PubMed  Google Scholar 

  111. Beltraminelli H, Leinweber B, Kerl H, Cerroni L. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol. 2009;31:317–22.

    Article  PubMed  Google Scholar 

  112. Cetinozman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol. 2012;36:109–16.

    Article  PubMed  Google Scholar 

  113. Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. 2003;102:2213–9.

    Article  CAS  PubMed  Google Scholar 

  114. Fink-Puches R, Zenahlik P, Back B, Smolle J, Kerl H, Cerroni L. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. 2002;99:800–5.

    Article  CAS  PubMed  Google Scholar 

  115. Garcia-Herrera A, Colomo L, Camos M, et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol. 2008;26(20):3364–71.

    Article  PubMed  Google Scholar 

  116. Grogg KL, Jung S, Erickson LA, McClure RF, Dogan A. Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol. 2008;21:708–15.

    Article  CAS  PubMed  Google Scholar 

  117. Beljaards RC, Meijer CJ, Van der Putte SC, et al. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma. J Pathol. 1994;172:53–60.

    Article  CAS  PubMed  Google Scholar 

  118. Rodriguez Pinilla SM, Roncador G, Rodriguez-Peralto JL, et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol. 2009;33:81–90.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands

    Rein Willemze

  2. Department of Medicine III, LMU Hospital, Munich, Germany

    Sebastian Theurich

  3. Department of Dermatology and Allergology, LMU Hospital, Munich, Germany

    Max Schlaak

Authors
  1. Rein Willemze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sebastian Theurich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Max Schlaak
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine III, LMU Hospital, München, Bayern, Germany

    Martin Dreyling

  2. Azienda Ospedaliera Nazionale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

    Marco Ladetto

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Willemze, R., Theurich, S., Schlaak, M. (2021). Indolent Cutaneous T-Cell Lymphomas. In: Dreyling, M., Ladetto, M. (eds) Indolent Lymphomas . Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-55989-2_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-55989-2_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-55988-5

  • Online ISBN: 978-3-030-55989-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation